Ken Griffin 4 D Molecular Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$10.81 - $27.22 $343,758 - $865,596	31,800 Added 538.98%	37,700 $407,000
Q2 2024 Aug 14, 2024	SELL	$20.93 - $30.01 $1.41 Million - $2.02 Million	-67,400 Reduced 91.95%	5,900 $123,000
Q1 2024 May 15, 2024	BUY	$17.03 - $35.87 $817,440 - $1.72 Million	48,000 Added 189.72%	73,300 $2.34 Million
Q4 2023 Feb 14, 2024	BUY	$9.76 - $21.25 $200,080 - $435,625	20,500 Added 427.08%	25,300 $512,000
Q3 2023 Nov 14, 2023	SELL	$12.64 - $19.76 $66,992 - $104,728	-5,300 Reduced 52.48%	4,800 $61,000
Q2 2023 Aug 14, 2023	BUY	$15.16 - $23.26 $48,512 - $74,432	3,200 Added 46.38%	10,100 $182,000
Q1 2023 May 15, 2023	SELL	$15.45 - $23.19 $191,580 - $287,556	-12,400 Reduced 64.25%	6,900 $118,000
Q4 2022 Feb 14, 2023	SELL	$6.85 - $25.46 $480,185 - $1.78 Million	-70,100 Reduced 78.41%	19,300 $428,000
Q3 2022 Nov 14, 2022	SELL	$6.96 - $11.48 $162,864 - $268,632	-23,400 Reduced 20.74%	89,400 $719,000

144

57.7M

137K

111K

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $180M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.